HER2-Positive Breast Carcinoma

molecular subtype

Identifier: CI-CAN-00007795
Entity page: /cancer/her2-positive-breast-carcinoma ↗
Edges: 557

Neighbours: 5 genes4 variants19 drugs10 trials
Drawn: 38 of 38 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,147 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
HER2-Positive Breast Carcinoma approved for …APPROVED_FOR3 of 3
← approved for	Neratinibsmall_molecule	supports	FDA ORIG	HER2-Positive Breast Carcinoma	1	Regulatory	openfda	graph →
← approved for	Margetuximabmonoclonal_antibody	supports	FDA ORIG

Paths

Strongest chains

Gene → variant → drug chains anchored in this cancer (or a descendant), ranked by source-native evidence level then support, with the approval and trial registry hops when they exist.

ERBB2 Amplification Trastuzumab39 active / 116 trials
Curatedlevel Asensitivity· support 14civicObservedcohort frequency not yet available for ERBB2 in this cancerno approval record in this cancercontext: HER2-Positive Breast Carcinoma
ERBB2 Amplification NeratinibFDA US 2017-07-177 active / 11 trials
Curatedlevel Asensitivity· support 2civicObservedcohort frequency not yet available for ERBB2 in this cancerRegulatoryapproved for HER2-Positive Breast Carcinoma (2 approval records)context: HER2-Positive Breast Carcinoma
ERBB2 Amplification Lapatinib0 active / 10 trials
Curatedlevel Bsensitivity· support 5civicObservedcohort frequency not yet available for ERBB2 in this cancerno approval record in this cancercontext: HER2-Positive Breast Carcinoma
ERBB2 Amplification Afatinib0 active / 2 trials
Curatedlevel Bsensitivity· support 4civicObservedcohort frequency not yet available for ERBB2 in this cancerno approval record in this cancercontext: HER2-Positive Breast Carcinoma
ERBB2 Amplification Trastuzumab Emtansine13 active / 27 trials
Curatedlevel Bsensitivity· support 4civicObservedcohort frequency not yet available for ERBB2 in this cancerno approval record in this cancercontext: HER2-Positive Breast Carcinoma
ERBB2 Amplification Capecitabine9 active / 24 trials
Curatedlevel Bsensitivity· support 2civicObservedcohort frequency not yet available for ERBB2 in this cancerno approval record in this cancercontext: HER2-Positive Breast Carcinoma
ERBB2 Amplification Docetaxel14 active / 28 trials
Curatedlevel Bsensitivity· support 2civicObservedcohort frequency not yet available for ERBB2 in this cancerno approval record in this cancercontext: HER2-Positive Breast Carcinoma
ERBB2 Amplification Pertuzumab28 active / 52 trials
Curatedlevel Bsensitivity· support 2civicObservedcohort frequency not yet available for ERBB2 in this cancerno approval record in this cancercontext: HER2-Positive Breast Carcinoma

Each hop keeps its own claim category: cohort alteration frequency (observed, cases ≥ 20), CIViC predictive edge (curated, level as stated by CIViC), regulatory approval (authority, jurisdiction, date as published), trial count (registry). A missing hop is shown as missing — never filled in. Not treatment guidance.

HER2-Positive Breast Carcinoma predicts response to …PREDICTS_RESPONSE_TO15 of 65show all (up to 200)
in context · predicts response to	ERBB2 Amplificationamplification → predicts response to Trastuzumab 2 source records aggregated	sensitivity	A	HER2-Positive Breast Carcinoma	2	Curated	civic	graph →
in context · predicts response to	ERBB2 Amplificationamplification → predicts response to Neratinib	sensitivity	A	HER2-Positive Breast Carcinoma	1	Curated	civic	graph →
in context · predicts response to	ERBB2 Amplificationamplification → predicts response to Trastuzumab 10 source records aggregated	sensitivity	B	HER2-Positive Breast Carcinoma	10	Curated	civic	graph →
in context · predicts response to	ERBB2 Amplificationamplification → predicts response to Lapatinib 5 source records aggregated	sensitivity	B	HER2-Positive Breast Carcinoma	5	Curated	civic	graph →
in context · predicts response to	ERBB2 Amplificationamplification → predicts response to Afatinib 4 source records aggregated	sensitivity	B	HER2-Positive Breast Carcinoma	4	Curated	civic	graph →
in context · predicts response to	ERBB2 Amplificationamplification → predicts response to Trastuzumab Emtansine 4 source records aggregated	sensitivity	B	HER2-Positive Breast Carcinoma	4	Curated	civic	graph →
in context · predicts response to	PTEN Lossdeletion_cna → predicts response to Trastuzumab 2 source records aggregated	resistance	B	HER2-Positive Breast Carcinoma	2	Curated	civic	graph →
in context · predicts response to	PIK3CA Mutationother → predicts response to Trastuzumab 2 source records aggregated	resistance	B	HER2-Positive Breast Carcinoma	2	Curated	civic	graph →
in context · predicts response to	ERBB2 Amplificationamplification → predicts response to Docetaxel 2 source records aggregated	sensitivity	B	HER2-Positive Breast Carcinoma	2	Curated	civic	graph →
in context · predicts response to	ERBB2 Amplificationamplification → predicts response to Pertuzumab 2 source records aggregated	sensitivity	B	HER2-Positive Breast Carcinoma	2	Curated	civic	graph →
in context · predicts response to	ERBB2 Amplificationamplification → predicts response to Capecitabine 2 source records aggregated	sensitivity	B	HER2-Positive Breast Carcinoma	2	Curated	civic	graph →
in context · predicts response to	PIK3CA Mutationother → predicts response to Lapatinib	resistance	B	HER2-Positive Breast Carcinoma	1	Curated	civic	graph →
in context · predicts response to	PIK3CA Mutationother → predicts response to Capecitabine	resistance	B	HER2-Positive Breast Carcinoma	1	Curated	civic	graph →
in context · predicts response to	ERBB2 Amplificationamplification → predicts response to Neratinib	sensitivity	B	HER2-Positive Breast Carcinoma	1	Curated	civic	graph →
in context · predicts response to	ERBB2 Overexpressionexpression → predicts response to Trastuzumab Emtansine	sensitivity	B	HER2-Positive Breast Carcinoma	1	Curated	civic	graph →

HER2-Positive Breast Carcinoma associated with …ASSOCIATED_WITH11 of 11
← associated with	ERBB2 2 source records aggregated	supports	A	HER2-Positive Breast Carcinoma	2	Curated	civic	graph →
← associated with	ERBB2 19 source records aggregated	supports	B	HER2-Positive Breast Carcinoma	19	Curated	civic	graph →
← associated with	PIK3CA 4 source records aggregated	supports	B	HER2-Positive Breast Carcinoma	4	Curated	civic	graph →
← associated with	PTEN 3 source records aggregated	supports	B	HER2-Positive Breast Carcinoma	3	Curated	civic	graph →
← associated with	BIRC5	supports	B	HER2-Positive Breast Carcinoma	1	Curated	civic	graph →
← associated with	PTEN	supports	C	HER2-Positive Breast Carcinoma	1	Curated	civic	graph →
← associated with	PIK3CA	supports	C	HER2-Positive Breast Carcinoma	1	Curated	civic	graph →
← associated with	PIK3CA 31 source records aggregated	supports	D	HER2-Positive Breast Carcinoma	31	Curated	civic	graph →
← associated with	PTEN 8 source records aggregated	supports	D	HER2-Positive Breast Carcinoma	8	Curated	civic	graph →
← associated with	ERBB2 4 source records aggregated	supports	D	HER2-Positive Breast Carcinoma	4	Curated	civic	graph →
← associated with	ERBB4	supports	D	HER2-Positive Breast Carcinoma	1	Curated	civic	graph →

HER2-Positive Breast Carcinoma investigated for …INVESTIGATED_FOR15 of 24show all (up to 200)
← investigated for	Trastuzumabmonoclonal_antibody 2 source records aggregated	supports	A	HER2-Positive Breast Carcinoma	2	Curated	civic	graph →
← investigated for	Neratinibsmall_molecule	supports	A	HER2-Positive Breast Carcinoma	1	Curated	civic	graph →
← investigated for	Trastuzumabmonoclonal_antibody 15 source records aggregated	supports	B	HER2-Positive Breast Carcinoma	15	Curated	civic	graph →
← investigated for	Lapatinibsmall_molecule 6 source records aggregated	supports	B	HER2-Positive Breast Carcinoma	6	Curated	civic	graph →
← investigated for	Trastuzumab Emtansineadc 5 source records aggregated	supports	B	HER2-Positive Breast Carcinoma	5	Curated	civic	graph →
← investigated for	Afatinibsmall_molecule 4 source records aggregated	supports	B	HER2-Positive Breast Carcinoma	4	Curated	civic	graph →
← investigated for	Capecitabinesmall_molecule 3 source records aggregated	supports	B	HER2-Positive Breast Carcinoma	3	Curated	civic	graph →
← investigated for	Docetaxelsmall_molecule 2 source records aggregated	supports	B	HER2-Positive Breast Carcinoma	2	Curated	civic	graph →
← investigated for	Pertuzumabmonoclonal_antibody 2 source records aggregated	supports	B	HER2-Positive Breast Carcinoma	2	Curated	civic	graph →
← investigated for	Everolimussmall_molecule 2 source records aggregated	supports	B	HER2-Positive Breast Carcinoma	2	Curated	civic	graph →
← investigated for	Neratinibsmall_molecule	supports	B	HER2-Positive Breast Carcinoma	1	Curated	civic	graph →
← investigated for	Fulvestrantsmall_molecule 2 source records aggregated	supports	C	HER2-Positive Breast Carcinoma	2	Curated	civic	graph →
← investigated for	Everolimussmall_molecule 2 source records aggregated	supports	C	HER2-Positive Breast Carcinoma	2	Curated	civic	graph →
← investigated for	Trastuzumabmonoclonal_antibody 17 source records aggregated	supports	D	HER2-Positive Breast Carcinoma	17	Curated	civic	graph →
← investigated for	Lapatinibsmall_molecule 9 source records aggregated	supports	D	HER2-Positive Breast Carcinoma	9	Curated	civic	graph →

HER2-Positive Breast Carcinoma investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 77show all (up to 200)
→ investigated in trials for	Trastuzumabmonoclonal_antibody 116 trials (39 active) · roll-up of the cancer and its descendants	—	—	HER2-Positive Breast Carcinoma	116	Observed	clinicaltrials	graph →
→ investigated in trials for	Pertuzumabmonoclonal_antibody 52 trials (28 active) · roll-up of the cancer and its descendants	—	—	HER2-Positive Breast Carcinoma	52	Observed	clinicaltrials	graph →
→ investigated in trials for	Paclitaxelsmall molecule 34 trials (15 active) · roll-up of the cancer and its descendants	—	—	HER2-Positive Breast Carcinoma	34	Observed	clinicaltrials	graph →
→ investigated in trials for	Docetaxelsmall_molecule 28 trials (14 active) · roll-up of the cancer and its descendants	—	—	HER2-Positive Breast Carcinoma	28	Observed	clinicaltrials	graph →
→ investigated in trials for	Trastuzumab Emtansineadc 27 trials (13 active) · roll-up of the cancer and its descendants	—	—	HER2-Positive Breast Carcinoma	27	Observed	clinicaltrials	graph →
→ investigated in trials for	Capecitabinesmall_molecule 24 trials (9 active) · roll-up of the cancer and its descendants	—	—	HER2-Positive Breast Carcinoma	24	Observed	clinicaltrials	graph →
→ investigated in trials for	Pyrotinibsmall molecule 24 trials (15 active) · roll-up of the cancer and its descendants	—	—	HER2-Positive Breast Carcinoma	24	Observed	clinicaltrials	graph →
→ investigated in trials for	Cyclophosphamidesmall molecule 22 trials (4 active) · roll-up of the cancer and its descendants	—	—	HER2-Positive Breast Carcinoma	22	Observed	clinicaltrials	graph →
→ investigated in trials for	Tucatinibsmall_molecule 19 trials (9 active) · roll-up of the cancer and its descendants	—	—	HER2-Positive Breast Carcinoma	19	Observed	clinicaltrials	graph →
→ investigated in trials for	Carboplatinsmall molecule 17 trials (8 active) · roll-up of the cancer and its descendants	—	—	HER2-Positive Breast Carcinoma	17	Observed	clinicaltrials	graph →
→ investigated in trials for	Neratinibsmall_molecule 11 trials (7 active) · roll-up of the cancer and its descendants	—	—	HER2-Positive Breast Carcinoma	11	Observed	clinicaltrials	graph →
→ investigated in trials for	Lapatinibsmall_molecule 10 trials (0 active) · roll-up of the cancer and its descendants	—	—	HER2-Positive Breast Carcinoma	10	Observed	clinicaltrials	graph →
→ investigated in trials for	Epirubicinsmall molecule 9 trials (2 active) · roll-up of the cancer and its descendants	—	—	HER2-Positive Breast Carcinoma	9	Observed	clinicaltrials	graph →
→ investigated in trials for	Letrozolesmall molecule 9 trials (4 active) · roll-up of the cancer and its descendants	—	—	HER2-Positive Breast Carcinoma	9	Observed	clinicaltrials	graph →
→ investigated in trials for	Doxorubicinsmall molecule 8 trials (3 active) · roll-up of the cancer and its descendants	—	—	HER2-Positive Breast Carcinoma	8	Observed	clinicaltrials	graph →

HER2-Positive Breast Carcinoma studied in …STUDIED_INderived10 of 377show all (up to 200)
→ studied in	NCT05132582Phase 3 · active not recruiting A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer · condition mapped ALIAS · 377 trials mapped (167 active)	—	—	HER2-Positive Breast Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05880160NA · completed Safety of Withdrawal of Pharmacological Treatment for Recovered HER2 Targeted Therapy Related Cardiac Dysfunction · condition mapped ALIAS · 377 trials mapped (167 active)	—	—	HER2-Positive Breast Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07152782Phase 2 · recruiting T-DXd With or Without Neratinib for HER2 Positive Breast Cancer With Brain Metastasis · condition mapped ALIAS · 377 trials mapped (167 active)	—	—	HER2-Positive Breast Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02945579NA · recruiting Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy · condition mapped ONTOLOGY_EXACT · 377 trials mapped (167 active)	—	—	HER2-Positive Breast Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07407920Phase 2 · recruiting Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial · condition mapped ONTOLOGY_EXACT · 377 trials mapped (167 active)	—	—	Early Stage HER2-Positive Breast Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03387553early Phase 1 · completed HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer · condition mapped ALIAS · 377 trials mapped (167 active)	—	—	HER2-Positive Breast Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07829900completed First-Line Dual Versus Single HER2-Targeted Therapy With Docetaxel for Advanced HER2-Positive Breast Cancer · condition mapped ALIAS · 377 trials mapped (167 active)	—	—	HER2-Positive Breast Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04585750Phase 1/Phase 2 · recruiting The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) · condition mapped ALIAS · 377 trials mapped (167 active)	—	—	HER2-Positive Breast Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05115474Phase 2 · recruiting Study of Screening Brain MRIs in Stage IV Breast Cancer · condition mapped ALIAS · 377 trials mapped (167 active)	—	—	HER2-Positive Breast Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05378464Phase 1 · suspended Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer · condition mapped ALIAS · 377 trials mapped (167 active)	—	—	HER2-Positive Breast Carcinoma	1	Observed	clinicaltrials	graph →